Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

PRLD Prelude Therapeutics Incorporated
$2.10 -3.25% -0.07
Notify me if price changes either direction
Interactive Brokers Logotype

Buy PRLD stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 132.0M
Enterprise value 140.5M
Trailing PE -1.2440475679579
Forward PE -1.834061
PEG Ratio 0.031467085542465
Enterprise to EBITDA -1.178
Enterprise to revenue 13.377
Price to book MRQ 2.7308192
Price to sales TTM 12.573053

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 10.5M
EBITDA -119267000
Diluted EPS TTM -1.47
Total Cash (MRQ) 55.0M
Current ratio (MRQ) 3.207
Operating Cash Flow (TTM) -100165000

PRLD trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent PRLD News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.